Table 3.
OAD used before and after GLP-1Ra treatment initiation
| n=217 | n=223 | |
|---|---|---|
| Number of OAD | Before GLP-1Ra | With GLP-1Ra |
| 1 | 76 (35.0%) | 0 |
| 2 | 83 (38.2%) | 145 (65.0%) |
| 3 | 52 (24.0%) | 71 (31.8%) |
| >3 | 6 (2.8%) | 7 (3.1%) |
| Mean number of OAD (SD) | 1.94 (0.8) | 2.39 (0.6) |
| Biguanide | ||
| Metformin | 199 (91.7%) | 214 (96.0%) |
| Sulfonylurea | ||
| Gliclazide | 47 (21.7%) | 41 (18.4%) |
| Glimepiride | 21 (9.7%) | 18 (8.1%) |
| Glibenclamide | 9 (4.1%) | – |
| Other | 2 (1.0%) | 2 (0.8%) |
| DPP-4 inhibitor | ||
| Sitagliptin | 57 (26.3%) | 2 (0.9%) |
| Vildagliptin | 33 (15.2%) | 3 (1.3%) |
| Other | 8 (3.7%) | 1 (0.4%) |
| Mitiglinide | ||
| Repaglinide | 30 (13.8%) | 15 (6.7%) |
| Glitazone | ||
| Pioglitazone | 13 (6.0%) | 11 (4.9%) |
| α glucosidase inhibitor | ||
| Acarbose | 1 (0.5%) | – |
DPP-4, dipeptidyl peptidase-4; GLP-1Ra, glucagon-like peptide-1 receptor agonists; OAD, oral antidiabetic drug.